Pancreatic Cancer Research

ResearcherThe University of SydneyActive in the last 2 years

Peter Grimison

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2653-1657; OpenAlex author ID A5023523143. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 9

  1. Portal venous circulating tumor cells as a biomarker for relapse prediction in resected pancreatic cancer. Co-author DOI 10.1007/s00018-025-05669-x↗
  2. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  3. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  4. Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells. Co-author DOI 10.3390/ijms23031671↗
  5. Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: a multicentre observational study. Last author DOI 10.1111/ans.17151↗
  6. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  7. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Co-author DOI 10.1038/s41467-019-10968-6↗
  8. Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Co-author DOI 10.1158/1078-0432.ccr-15-0426↗
  9. Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma. Last author DOI 10.1111/imj.12415↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dannel Yeo · 2 shared papers, 2022–2025 · strength 0.40
  2. John E.J. Rasko · 2 shared papers, 2022–2025 · strength 0.40
  3. Charbel Sandroussi · 2 shared papers, 2021–2025 · strength 0.34
  4. Jaswinder Singh Samra · 2 shared papers, 2015–2021 · strength 0.16
  5. Andrew Ohyama Parsonson · 1 shared paper, 2021 · strength 0.13
  6. Neil Donald Merrett · 1 shared paper, 2021 · strength 0.13
  7. George Hruby · 1 shared paper, 2021 · strength 0.13
  8. Anubhav Mittal · 1 shared paper, 2021 · strength 0.13
  9. Alice Grey · 1 shared paper, 2014 · strength 0.05
  10. Jeremy L. Humphris · 1 shared paper, 2015 · strength 0.03
  11. Angela S. Y. Chou · 1 shared paper, 2015 · strength 0.03
  12. Nick Pavlakis · 1 shared paper, 2015 · strength 0.03
  13. Amber L. Johns · 1 shared paper, 2015 · strength 0.03
  14. David Morgan Thomas · 1 shared paper, 2015 · strength 0.03
  15. Marina Pajic · 1 shared paper, 2015 · strength 0.03
  16. Venessa T. Chin · 1 shared paper, 2015 · strength 0.03
  17. Lorraine A. Chantrill · 1 shared paper, 2015 · strength 0.03
  18. Sean Michael Grimmond · 1 shared paper, 2015 · strength 0.03
  19. Anthony James Gill · 1 shared paper, 2015 · strength 0.03
  20. Adnan M. Nagrial · 1 shared paper, 2015 · strength 0.03
  21. David Kuang-Fu Chang · 1 shared paper, 2015 · strength 0.03
  22. Andrew Victor Biankin · 1 shared paper, 2015 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.